JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katz, S. M.
Right arrow Articles by Bishop, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Katz, S. M.
Right arrow Articles by Bishop, M. J.

Anesth Analg 2004;98:272
© 2004 International Anesthesia Research Society

LETTERS TO THE EDITOR

Mivacurium and Bronchospasm

Steven M. Katz, MD, JD

Healthsouth Northwest Surgicare, Arlington Heights, Illinois

To the Editor:

The authors of the case report regarding mivacurium and bronchospasm (1) draw a conclusion with serious medicolegal implications. They state "that extreme caution be exercised in the administration of mivacurium to patients at risk for bronchospasm (as suggested by the manufacturer) and that alternative drugs be considered for such patients (1)." The authors provide litigation support, and, consequently, their conclusion may be biased. Just as there is disclosure of an author’s relationship with a pharmaceutical company or device manufacturer, it would be worthwhile for your readers to know the nature of these authors’ relationship with the legal process, and whether most of their consultative work is done for plaintiffs or defendants.

Reference

  1. Bishop MJ, O’Donnell JT, Salemi JR. Mivacurium and bronchospasm. Anesth Analg 2003; 97: 484–5.[Abstract/Free Full Text]
 

Response

Michael J. Bishop, MD

Anesthesiology and Medicine (Adjunct), University of Washington School of Medicine, VA Puget Sound Health Care System, Seattle, WA

In Response:

I am not a lawyer and cannot speak to any medicolegal implications of the article. However, I am happy to provide the disclosure information requested by Dr Katz. My involvement in the cases mentioned included one as a defense witness and three for which I performed an initial review but did not serve as an expert. Dr O’Donnell and Mr. Salemi work for Pharmaconsultant, which provided the technical expertise to extract the data from the FDA data set. Pharmaconsultant provides pharmaceutical consultation for a variety of legal and governmental clients and counts both plaintiffs’ attorneys and defendants’ attorneys among its clients.

The motivation for this paper was patient safety and to raise awareness of a side effect that is actually noted in the existing package insert.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katz, S. M.
Right arrow Articles by Bishop, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Katz, S. M.
Right arrow Articles by Bishop, M. J.

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press